6-Amino-8-(((aminocarbonyl)oxy)-methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino-(2',3': 3,4)pyrrolo(1,2-a)indol-4,7-dion,(1aS-(1a alpha, 8 beta, 8a alpha,8b alpha))-

Mitomycin C Struktur
50-07-7
CAS-Nr.
50-07-7
Bezeichnung:
6-Amino-8-(((aminocarbonyl)oxy)-methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino-(2',3': 3,4)pyrrolo(1,2-a)indol-4,7-dion,(1aS-(1a alpha, 8 beta, 8a alpha,8b alpha))-
Englisch Name:
Mitomycin C
Synonyma:
MITOMYCIN;MMC;MITOMYCIN A;AMETYCIN;MITOCIN C;Mitomicin C;azirino(2’,3’:3,4)pyrrolo(1,2-a)indole-4,7-dione,6-amino-1,1a,2,8,8a,8b-hexahy;azirino[2’,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione,6-amino-8-[[(aminocarbonyl)ox;Azirino2,3:3,4pyrrolo1,2-aindole-4,7-dione, 6-amino-8-(aminocarbonyl)oxymethyl-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)-;Azirino[2’,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione,6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-[1aS-(1aalpha,8beta,8aalpha,8balpha)]-
CBNumber:
CB8456544
Summenformel:
C15H18N4O5
Molgewicht:
334.33
MOL-Datei:
50-07-7.mol

6-Amino-8-(((aminocarbonyl)oxy)-methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino-(2',3': 3,4)pyrrolo(1,2-a)indol-4,7-dion,(1aS-(1a alpha, 8 beta, 8a alpha,8b alpha))- Eigenschaften

Schmelzpunkt:
360 °C
Siedepunkt:
471.14°C (rough estimate)
Dichte
1.2238 (rough estimate)
Brechungsindex
1.6800 (estimate)
storage temp. 
2-8°C
Löslichkeit
H2O: 4 mL/vial Stock solutions should be filter sterilized and stored at 2-8 °C in the dark., clear to slightly hazy, blue to purple
Aggregatzustand
powder
pka
pKa 2.8(H2O,t =25,I=0.1) (Uncertain)
Farbe
blue-gray
PH
pH (0.5 g/l, 25℃ : )5.0~7.0
Wasserlöslichkeit
soluble
Merck 
14,6215
BRN 
7231816
Stabilität:
Stable. Incompatible with strong acids, strong bases, strong oxidizing agents.
CAS Datenbank
50-07-7(CAS DataBase Reference)
IARC
2B (Vol. 10, Sup 7) 1987
EPA chemische Informationen
Mitomycin C (50-07-7)
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Kennzeichnung gefährlicher T,Xn,T+
R-Sätze: 25-40-22-45-26/27/28
S-Sätze: 36/37-45-28A-28-53-22
RIDADR  UN 3462 6.1/PG 2
WGK Germany  3
RTECS-Nr. CN0700000
8-10
TSCA  Yes
HazardClass  6.1(a)
PackingGroup  II
HS Code  29419090
Giftige Stoffe Daten 50-07-7(Hazardous Substances Data)
Toxizität LD50 i.v. in mice: 5 mg/kg (Wakaki); also reported as 9 mg/kg (Kinoshita)
Bildanzeige (GHS) GHS hazard pictogramsGHS hazard pictograms
Alarmwort Achtung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H300 Lebensgefahr bei Verschlucken. Akute Toxizität oral Kategorie 2 Achtung GHS hazard pictogramssrc="/GHS06.jpg" width="20" height="20" /> P264, P270, P301+P310, P321, P330,P405, P501
H351 Kann vermutlich Krebs verursachen. Karzinogenität Kategorie 2 Warnung P201, P202, P281, P308+P313, P405,P501
Sicherheit
P201 Vor Gebrauch besondere Anweisungen einholen.
P202 Vor Gebrauch alle Sicherheitshinweise lesen und verstehen.
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P270 Bei Gebrauch nicht essen, trinken oder rauchen.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P301+P310 BEI VERSCHLUCKEN: Sofort GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.

6-Amino-8-(((aminocarbonyl)oxy)-methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino-(2',3': 3,4)pyrrolo(1,2-a)indol-4,7-dion,(1aS-(1a alpha, 8 beta, 8a alpha,8b alpha))- Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:

R25:Giftig beim Verschlucken.
R40:Verdacht auf krebserzeugende Wirkung.
R22:Gesundheitsschädlich beim Verschlucken.
R45:Kann Krebs erzeugen.
R26/27/28:Sehr giftig beim Einatmen, Verschlucken und Berührung mit der Haut.

S-Sätze Betriebsanweisung:

S36/37:Bei der Arbeit geeignete Schutzhandschuhe und Schutzkleidung tragen.
S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).
S28:Bei Berührung mit der Haut sofort abwaschen mit viel . . . (vom Hersteller anzugeben).
S53:Exposition vermeiden - vor Gebrauch besondere Anweisungen einholen.
S22:Staub nicht einatmen.

Beschreibung

Mitomycin C is naturally produced by Streptomyces caespitosus, an Actinobacteria found in soil. Mitomycin C has antibiotic and antitumor activities and has been studied extensively since the 1950s. A unique feature of this drug is strong bioreductive alkylation under hypoxic conditions. Oxygen-poor cells internal to solid tumors provide an environment in which this drug is highly activated. As an antitumor agent, it has shown efficacy in a wide variety of cancers, including gastric cancer, pancreatic cancer, breast cancer, non-small-cell lung cancer, cervical cancer, prostate cancer, and bladder cancer. The sideeffect profile is large, which prohibits its widespread use. Mitomycin C is antibacterial to gram-positive, gram-negative, and acid-fast bacilli.

Chemische Eigenschaften

Blue-violet crystals or crystalline powder.

Verwenden

Mitomycin C is the most studied of a family of highly distinctive blue/purple metabolites produced by several Streptomyces species. Mitomyin C exhibits potent antibacterial and antitumour activity and inhibits DNA synthesis by intercalation, blocking nuclear division with the induction of apoptosis in cancer cells.

Definition

Antibiotic derivedfrom Streptomyces, stated to be effective againsttumors.

Indications

Mitomycin (mitomycin C, Mitocin-C, Mutamycin) is an antibiotic that is derived from a species of Streptomyces. It is sometimes classified as an alkylating agent because it can covalently bind to and cross-link DNA. Mitomycin is thought to inhibit DNA synthesis through its ability to alkylate double-strand DNA and bring about interstrand cross-linking. There is evidence that enzymatic reduction by a reduced nicotinamide– adenine dinucleotide phosphate (NADPH) dependent reductase is necessary to activate the drug.
The drug is rapidly cleared from serum after intravenous injection but is not distributed to the brain.

Allgemeine Beschreibung

Blue-violet crystals. Used as an anti-tumor antibiotic complex.

Air & Water Reaktionen

Water soluble.

Reaktivität anzeigen

Mitomycin C is sensitive to prolonged exposure to light. Mitomycin C may be sensitive to prolonged exposure to air. Mitomycin C is incompatible with strong oxidizing agents, strong acids and strong bases. Calcium salts may cause decomposition.

Hazard

Possible carcinogen.

Health Hazard

Toxic doses as low as 750 mg/kg have been reported in humans. The major toxic effect is myelosuppression, characterized by marked leukopenia and thrombocytopenia; this may be delayed and cumulative. Interstitial pneumonia and glomerular damage resulting in kidney failure are unusual but well documented complications. Lung conditions -- administration of mitomycin has been recognized as causing pneumonitis, alveolitis and pulmonary fibrosis. Kidney conditions -- administration of Mitomycin Can cause kidney damage. Kidney toxicity was observed in 1-5 percent of patients. Depressed immune conditions.

Brandgefahr

Flash point data for Mitomycin C are not available; however, Mitomycin C is probably combustible.

Biologische Aktivität

Antibiotic and antitumor agent. Covalently binds DNA forming intra- and interstrand crosslinks. Inhibits DNA synthesis.

Clinical Use

Mitomycin has limited palliative effects in carcinomas of the stomach, pancreas, colon, breast, and cervix.

Nebenwirkungen

The major toxicity associated with mitomycin therapy is unpredictably long and cumulative myelosuppression that affects both white blood cells and platelets. A syndrome of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure also has been described. Renal, hepatic, and pulmonary toxicity may occur. The drug is teratogenic and carcinogenic, and it can cause local blistering.

mögliche Exposition

This compound is an antitumor antibiotic complex. This drug is usually injected intravenously.

Environmental Fate

Mitomycin C is naturally produced by S. caespitosus, a microorganism found in soil and decaying vegetation. As a compound potentially released in commercial solid waste or in spill or container residue, mitomycin C is not thought to persist in soil and water. Calculations based on its hydrolysis rate in water at 25 ℃ show a half-life of 12.9 days. It is readily soluble in water, so mobility in groundwater is high. Mitomycin persistence in air is low and bioaccumulation is low.

Stoffwechsel

Mitomycin is administered IV in the treatment of disseminated adenocarcinoma of the stomach or pancreas, and it has been used intravesically in superficial bladder cancer. Biotransformation pathways are saturable, and approximately 10% of an administered dose is eliminated unchanged via the kidneys.

Versand/Shipping

UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required. UN3249 Medicine, solid, toxic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials.

läuterung methode

Mitomycin C forms blue-violet crystals from *C6H6/pet ether. It is soluble in Me2CO, MeOH and H2O, moderately soluble in *C6H6, CCl4 and Et2O but insoluble in pet ether. It has UV max at 216, 360 and a weak peak at 560nm in MeOH. [Stevens et al. J Med Chem 8 1 1965, Shirahata & Hirayama J Am Chem Soc 105 7199 1983, Beilstein 25 III/IV 516.]

Inkompatibilitäten

Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides, heat, strong light, calcium salts.

Waste disposal

Consult with environmental regulatory agencies for guidance on acceptable disposal practices. Generators of waste containing this contaminant (≥100 kg/mo) must conform to EPA regulations governing storage, transportation, treatment, and waste disposal. It is inappropriate and possibly dangerous to the environment to dispose of expired or waste drugs and pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged, and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

6-Amino-8-(((aminocarbonyl)oxy)-methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino-(2',3': 3,4)pyrrolo(1,2-a)indol-4,7-dion,(1aS-(1a alpha, 8 beta, 8a alpha,8b alpha))- Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


6-Amino-8-(((aminocarbonyl)oxy)-methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino-(2',3': 3,4)pyrrolo(1,2-a)indol-4,7-dion,(1aS-(1a alpha, 8 beta, 8a alpha,8b alpha))- Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 183)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Shanghai Minbiotech Co., Ltd.
+8617315815539
sales@minbiotech.com CHINA 129 58
Hangzhou Benoy Chemical Co., Ltd
+8617342059697
sales@benoychem.com China 315 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 29322 58
Hebei Mojin Biotechnology Co., Ltd
+8613288715578
sales@hbmojin.com China 12457 58
Hebei Yanxi Chemical Co., Ltd.
+8617531190177
peter@yan-xi.com China 5993 58
Changzhou Rokechem Technology Co., Ltd.
18758118018
sales001@rokechem.com China 255 58
Shaanxi Haibo Biotechnology Co., Ltd
+undefined18602966907
qinhe02@xaltbio.com China 1000 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21695 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32480 60
Hebei Guanlang Biotechnology Co., Ltd.
+86-19930503282
alice@crovellbio.com China 8823 58

50-07-7(6-Amino-8-(((aminocarbonyl)oxy)-methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino-(2',3': 3,4)pyrrolo(1,2-a)indol-4,7-dion,(1aS-(1a alpha, 8 beta, 8a alpha,8b alpha))-)Verwandte Suche:


  • Mitomycin C(Ametycine)
  • Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-
  • Mytomycin C
  • [1aR-(1aα,8β,8aα,8bα)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-α]indole-4,7-dione
  • 6-Amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methox-5-methylazirino[2',3':3,4]pyrrolo[1,2-
  • MitonyycinC
  • [1aS-(1aα,8β,8aα,8bα)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione
  • 8balpha)]-8aalph
  • ametycine
  • azirino(2’,3’:3,4)pyrrolo(1,2-a)indole-4,7-dione,6-amino-8-(((aminocarbonyl)oxy
  • mitomycinum
  • mitomycynac
  • mitomycynac(polish)
  • mytomycin
  • nci-c04706
  • nsc26980
  • nsc-26980
  • rcrawastenumberu010
  • y]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-,[1as-(1aalpha,8beta,
  • 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione carbamate (ester)
  • MITOMYCIN C
  • MITOMYCIN C, STREPTOMYCES CAESPITOSUS
  • MUTAMYCIN
  • mitomycin C from streptomyces*caespitosus
  • MITOMYCIN C, VIAL WITH 2 MG*
  • MITOMYCIN C FROM STREPTOMYCES*CAESPITOSU S CELL CULT
  • MitomycinCuSp28
  • MitomycinC,4%inNaCl
  • MitomycinC/NaCl
  • Mitomycin C, contains 2 mg Mitomycin C and 48 mg NaCl
  • Mitomycin C, carrier-free
  • MITOMYCIN,USP
  • Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-, carbamate (ester) (8CI)
  • Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1aS,8S,8aR,8bS)- (9CI)
  • Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1aa,8b,8aa,8ba)]-
  • MitoExtra
  • Mitonco
  • Mitoplus
  • MITOMICYNC
  • Mitoycin C
  • [1ar-(1aalpha,8beta,8aalpha,8balpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-alpha]indole-4,7-dione
  • MITOMYCIN C (2MG) IN 48MG SODIUM CHLORIDE
  • Mitomycin C, Mutamycin, Ametycin, Mitocin-C
  • MITIGLINIDECALCIUMHYDRATE
  • [1aS-(1aa,8,8aa,8ba)-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2,’3’:3,4]pyrrolo[1,2-a]indole-4,7-dione
  • Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-, carbamate (ester)
  • Mitomycin (50 mg)
  • [(4S,6S,7R,8S)-11-aMino-7-Methoxy-12-Methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0^{2,7}.0^{4,6}]trideca-1(9),11-dien-8-yl]Methyl carbaMate
  • MitoMyci
  • AMETYCIN,MitoMycin C
  • MitoMycin, MitoMycin S, MitiroMycin E, AMetycine, Mitocin C, MutaMycin, NSC 26980
  • Mitomycin C, >=99%
  • )methyl)-1,1a,2,8,8a,8b-hexahydro-8-a-methoxy-5-methyl-,(1as-(1aalpha,8beta,
  • 7-amino-9-alpha-methoxymitosane
  • 8aalpha,8balpha))-(9ci)
  • Mitomycin (1444707)
  • 0/7/50
  • Mitomycins-C
Copyright 2019 © ChemicalBook. All rights reserved